Elaheremirvetuximab soravtansine · FRαRationale not stated; FIH Study 0401 escalated from 0.15 mg/kg (TBW) to 7.0 mg/kg
Enhertufam-trastuzumab deruxtecan · HER21/12 HED of monkey HNSTD (0.8 mg/kg), also matching minimum effective trough concentration
Kadcylaado-trastuzumab emtansine · HER2HNSTD-based: monkey HNSTD 10 mg/kg (q3w x4), below 1/10 rat severely toxic dose, used to set Phase I start
Zynlontaloncastuximab tesirine · CD191/6 HNSTD in cynomolgus monkey cited as rationale for species choice; actual FIH calculation not detailed